Zepbound vs. Mounjaro: Why the Same Drug Has Two Names and Two Prices

Zepbound and Mounjaro contain identical molecules — tirzepatide, a dual GIP/GLP-1 receptor agonist made by Eli Lilly — but exist as separate branded products because the U.S. regulatory and insurance systems treat diabetes drugs and obesity drugs as categorically different. The practical consequence: the same injection can cost you dramatically more or less depending on which box it came in.

One Molecule, Two FDA Approvals

Tirzepatide entered the U.S. market as Mounjaro in May 2022, approved for type 2 diabetes. Lilly then ran the SURMOUNT-1 trial — published in NEJM — showing 20.9% average weight loss over 72 weeks in adults with obesity, and obtained a separate FDA approval in November 2023 under the name Zepbound for chronic weight management (BMI ≥30, or ≥27 with a weight-related comorbidity). Zepbound later added an obstructive sleep apnea indication in 2024.

This dual-brand strategy mirrors what Novo Nordisk did with semaglutide — Ozempic for diabetes, Wegovy for obesity — and it's driven by U.S. market structure, not pharmacology. In Europe, the same molecule was simply added to the existing Mounjaro label. No Zepbound needed.

For a deeper breakdown of how tirzepatide stacks up against semaglutide on efficacy, see our comparison of tirzepatide vs. semaglutide for weight loss.

Why the Price Differs

The divergence comes down to insurance formularies. Most commercial plans that cover Mounjaro require a type 2 diabetes diagnosis and run it through their diabetes benefit. Zepbound falls under anti-obesity medication coverage — which many plans exclude entirely or fence behind separate prior-authorization criteria.

List prices (both roughly $1,000+/month without assistance) are similar, but real out-of-pocket costs diverge sharply:

• Mounjaro savings card: eligible commercially insured patients with T2D can pay as little as $25/month
• Zepbound savings card: separate program for obesity indication; terms differ and T2D diagnosis isn't required
• Medicare: covers Zepbound KwikPen only through the GLP-1 Bridge program; single-dose pens and vials are excluded

Patients without diabetes who need tirzepatide for weight loss often face the full list price for Zepbound unless their plan has obesity coverage — or they find a prescriber willing to write Mounjaro off-label. Neither workaround is ideal, and coverage gaps are the primary driver of non-adherence in practice.

If you're comparing providers who prescribe tirzepatide for weight loss, the weight management treatment hub at Alpha Health Finder lists options by cost tier and insurance compatibility. Providers like Marek Health work with patients on both branded and compounded tirzepatide pathways.

For a side-by-side look at how Mounjaro and Wegovy compare in practice, our editorial on Mounjaro vs. Wegovy covers the efficacy data in detail.

Frequently asked questions

Are Zepbound and Mounjaro the same drug?

Zepbound and Mounjaro are pharmacologically identical — both contain tirzepatide at the same dose strengths (2.5 mg through 15 mg, once weekly). The difference is FDA indication: Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and obesity-related obstructive sleep apnea. Lilly created two brands to align each product with separate insurance formularies and patient-assistance programs, not because the molecules differ.

Can I use Mounjaro for weight loss if I don't have diabetes?

Mounjaro can be prescribed off-label for weight loss in patients without type 2 diabetes, and clinically it produces the same results — SURMOUNT-1 data showed ~20.9% weight loss at 72 weeks regardless of brand name. The catch is cost: Mounjaro's manufacturer savings card requires a diabetes diagnosis, so patients without T2D typically can't access the deepest discounts and may pay more out-of-pocket than they would for Zepbound with obesity coverage.

Which is cheaper in 2026 — Zepbound or Mounjaro?

It depends entirely on your insurance. For patients with type 2 diabetes on commercial insurance, Mounjaro is often cheaper due to diabetes-specific formulary placement and savings card eligibility. For patients seeking weight management without a diabetes diagnosis, Zepbound is the on-label option, but coverage varies widely — many plans still exclude anti-obesity medications. Compounded generic tirzepatide through 503A/503B pharmacies remains a lower-cost alternative for cash-pay patients, though availability fluctuates with FDA shortage designations.